Monthly Round-Up of What to Read on Pharma Law and Policy
Bill of Health
NOVEMBER 17, 2022
Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study. Medicare’s National Coverage Determination for Aducanumab – A One-Off or a Pragmatic Path Forward? Medicaid Spending on Antiretrovirals from 2007-2019.
Let's personalize your content